MiniMed (Nasdaq: MMED) today reported Street-beating first-quarter revenue, upping its full-year sales guidance as it notched an early European regulatory win. The Northridge, California–based diabetes tech company, spun out of Medtronic earlier this year, announced a CE mark for its next-gen, app-controlled MiniMed Flex insulin pump — well ahead of the company’s calendar 2026 year-end target. […]
MassDevice Earnings Roundup
Embecta Q3 results beat analyst expectations
Julia Rock-Torcivia Embecta Corp. (Nasdaq: EMBC) raised its full-year outlook for adjusted earnings per share as third-quarter results beat analyst estimates. The medtech company, a BD spinoff that specializes in insulin delivery, reported last week net income of $21.1 million, or $0.36 per share, on revenue of $271.7 million for the three months ended June […]
ICU Medical Q2 results beat analyst expectations, driven by infusion systems
Julia Rock-Torcivia ICU Medical (Nasdaq: ICUI) reported second quarter results that beat Wall Street expectations, upping its full-year guidance. San Clemente, California–based ICE Medical, which specializes in IV therapy, infusion pumps and closed-system drug transfer devices, reported income of $19.1 million, or 76¢ per share, on revenue of $551.7 million for the three months ended June […]
Senseonics more than doubles Q2 revenue in post-Ascensia era
Senseonics (NYSE:SENS) stock is up more than 26% today after it reported what CEO Tim Goodnow described as the strongest quarter in the implantable, long-term CGM company’s history. BTIG analysts Marie Thibault, Alexandra Pang, and Sam Eiber noted that the European commercial transition from Ascensia Diabetes Care closed in June across all four markets, bringing […]
Tandem Diabetes Care seeing early benefits of new pay-as-you-go model
Tandem Diabetes Care (Nasdaq: TNDM) says U.S. sales of its insulin pumps were boosted by a scaled pay-as-you-go reimbursement model that’s been rolling out this year. According to the San Diego–based company’s second-quarter report, released after market close yesterday, the alternative reimbursement structure, available through patients’ pharmacy benefits rather than medical benefits, eliminates upfront pump […]
Insulet slightly lowers 2026 sales growth outlook despite Q2 beats
Insulet (Nasdaq:PODD) slightly lowered its 2026 sales growth guidance despite second-quarter results that handily beat Wall Street estimates. The company previously projected total annual sales growth between 21% and 23%. However, it lowered that outlook by 1 percentage point at each end to 20%-22%. The company did increase its adjusted EPS guidance, though, expecting growth […]
Dexcom Q2 results beat expectations, lead to increased sales outlook
Dexcom (Nasdaq:DXCM) today reported second-quarter results that came in ahead of the consensus Wall Street forecast. Shares of DXCM rose 2% to $76.02 apiece after the market closed today. The San Diego-based continuous glucose monitor (CGM) maker reported profits of $249.1 million. That equals 64¢ per share on sales of $1.31 billion for the three […]
Beta Bionics posts Q2 beats on 38% sales growth
Beta Bionics (Nasdaq:BBNX) today reported second-quarter financial results that topped the consensus estimates on Wall Street. Shares of BBNX remained unmoved at $15.17 apiece after the market closed today. The Irvine, California-based automated insulin delivery technology developer reported losses of $23.4 million in the quarter. That equals 53¢ per share on sales of $32 million […]
MiniMed adds Abbott dual glucose-ketone sensor to portfolio, posts Q4 sales beat
MiniMed (Nasdaq:MMED) announced today that it expanded its agreement with Abbott (NYSE:ABT) to add more sensors to its portfolio. The company also announced fourth-quarter earnings results in tandem with the new Abbott integration. MiniMed has an existing partnership with Abbott through a collaboration between the companies agreed in 2024. They integrated Instinct, a sensor made by […]
Senseonics posts mixed Q1, raises 2026 guidance amid growing Eversense 365 sales
Senseonics (NYSE:SENS) today reported first-quarter financial results that exceeded Wall Street’s revenue expectations. However, shares of SENS ticked up 1.4% to $5.43 apiece in post-market trading today as the company reported recent advances with its diabetes technology and increased its guidance. The Germantown, Maryland-based long-term implantable continuous glucose monitor (CGM) maker reported losses of $32.3 […]
